Efficacy, Safety and PK of Once‐Daily Oral Semaglutide 25 mg for Obesity With and Without Type 2 Diabetes in Comparison With Subcutaneous Semaglutide 2.4 mg: A Model‐Informed Drug Development Approach

Fuente: Wiley Open Access

Saved in:

Bibliographic Details
Main Authors:	Rune Viig Overgaard, Oscar Birkhan, Naveen Rathor, Thomas Sparsø, Anders Strathe, Sean Wharton, Domenica Rubino
Format:	Artículo Open Access
Published:	Wiley 2026
Subjects:	Diabetes, Obesity and Metabolism
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Internet